Together with our updated review (minus the eight unpublished trials included in the Kaiser meta-analysis), the BMJ published several linked articles in one issue, almost constituting a monograph.
The editor-in-chief, Godlee, asked why we could not have access to data for a drug in which the public purse had invested billions. Deborah Cohen, who had led …
Keep reading with a 7-day free trial
Subscribe to Trust the Evidence to keep reading this post and get 7 days of free access to the full post archives.